Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.73 |
| ▸ | CTSK | P43235 | 3/20 | 0.73 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.66 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.56 |
| ▸ | PPARA | Q07869 | 5/20 | 0.52 |
| ▸ | PPARG | P37231 | 4/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL270318 | 1.00 | CTSS (0.73) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL29907906 | 1.00 | CTSS (0.73) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL29401585 | 1.00 | CTSS (0.73) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL270319 | 1.00 | CTSS (0.73) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL23722980 | 0.90 | CTSS (0.60) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL4663077 | 0.87 | CTSK (0.60) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL8238593 | 0.87 | CTSK (0.60) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL13743658 | 0.87 | CTSK (0.60) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL12851291 | 0.87 | CTSS (0.73) | CTSSCTSKPTPN1SCN9ASCN10A | |
| SCHEMBL3006752 | 0.86 | CTSS (0.55) | CTSSCTSKPTPN1ACESCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20240057599-A1 | METHODS FOR IMPROVING FRUIT QUALITY | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2024-02-22 | — | — | US | disclosed |
| US-11812746-B2 | Method of controlling fungal infections in plants | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2023-11-14 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230138310-A1 | PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND | FRONTIER BIOTECHNOLOGIES INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20220194935-A1 | PHENETHYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2022-06-23 | — | — | US | disclosed |
| EP-3983408-A1 | PHENETHYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP | 3M Innovative Properties Company (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-113906027-A | Phenethyl substituted imidazo [4,5-c ] quinoline compounds with N-1 branched groups | 3M创新有限公司 | 2022-01-07 | — | — | CN | disclosed |
| WO-2020250089-A1 | PHENETHYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5556853-A | THIOL PROTEASE INHIBITORS, TREATMENT OF OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0720601-A1 | GASTRIN AND CCK RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| EP-0719251-A1 | BICYCLO (2.2.2) OCTANE DERIVATIVES CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-07-03 | — | — | EP | disclosed |
| US-5514683-A | LIGANDS FKOR CHOLECYSTOKININ OR GASTRIN RECEPTORS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-05-07 | — | — | US | disclosed |
| WO-1995032949-A1 | GASTRIN AND CCK ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995030647-A1 | CCK AND GASTRIN RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1995-11-16 | — | — | WO | disclosed |
| EP-0655447-A1 | Epoxysuccinic acid derivatives | Takeda Chemical Industries, Ltd. (JP) | 1995-05-31 | — | — | EP | disclosed |
| WO-1995005359-A1 | BICYCLO (2.2.2) OCTANE DERIVATIVES CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
| WO-1995004720-A2 | GASTRIN AND CCK RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | CTSS 4022/4885CTSK 4661/4885PTPN1 827/4885 |
| US-20230138310-A1 | PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND | ACE, ACE2, TMPRSS2 | CTSS 73/4885CTSK 176/4885PTPN1 2664/4885 |
| US-20220194935-A1 | PHENETHYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP | IFNG, IFNAR1, IRF3 | CTSS 2585/4885CTSK 3054/4885PTPN1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.